(2S)-(+)-1-BENZOYL-2-TERT-BUTYL-3-METHYL-4-IMIDAZOLIDINONE structure
|
Common Name | (2S)-(+)-1-BENZOYL-2-TERT-BUTYL-3-METHYL-4-IMIDAZOLIDINONE | ||
|---|---|---|---|---|
| CAS Number | 175553-48-7 | Molecular Weight | 393.43400 | |
| Density | N/A | Boiling Point | 741.2ºC at 760mmHg | |
| Molecular Formula | C19H27N3O6 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 402.1ºC | |
Use of (2S)-(+)-1-BENZOYL-2-TERT-BUTYL-3-METHYL-4-IMIDAZOLIDINONEButabindide (UCL-1397) is a potent, selective tripeptidvl peptidase II (TPP II) inhibitor with Ki values of 7 nM and 10 μM for TPP II and TPP I, respectively. Butabindide inhibits TPP II to protect CCK-8 against inactivation[1][2]. |
| Name | 1-(6-amino-5-oxooctan-4-yl)-2,3-dihydroindole-2-carboxamide,oxalate |
|---|
| Description | Butabindide (UCL-1397) is a potent, selective tripeptidvl peptidase II (TPP II) inhibitor with Ki values of 7 nM and 10 μM for TPP II and TPP I, respectively. Butabindide inhibits TPP II to protect CCK-8 against inactivation[1][2]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 7 nM (TPP II) and 10 μM (TPP I)[1] |
| In Vitro | Butabindide (UCL-1397; 0-24 nM; membranes of rat cerebral cortex) inhibits TPP II activity of cerebral membranes[2]. |
| In Vivo | Butabindide (UCL-1397; 10 mg/kg; i.v.; for 20 min) inhibits the breakdown of CCK-8 in the gastrointestinal tract and increases satiety in mice[2]. Animal Model: Mice (25-30 g) Dosage: 10 mg/kg Administration: Intravenous injection; for 20 minutes Result: Reduces food intake and elicits other behavioral concomitants of satiation. |
| References |
| Boiling Point | 741.2ºC at 760mmHg |
|---|---|
| Molecular Formula | C19H27N3O6 |
| Molecular Weight | 393.43400 |
| Flash Point | 402.1ºC |
| Exact Mass | 393.19000 |
| PSA | 150.03000 |
| LogP | 1.90970 |
| Vapour Pressure | 4.53E-23mmHg at 25°C |